SOUTH SAN FRANCISCO, Calif., November 17, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. TNJA, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 22,613,307 common shares at a public price announced of $2.60 per share and prefunded warrants to certain investors in lieu of common shares to purchase an aggregate of up to 6,236,693 shares of its common stock at a purchase price of $2.599 per prefunded warrant, being the price per share at the public offering price for the common stock less the exercise price of $0.001 per share for each such prefunded warrant. All securities are to be sold by Tenaya. In addition, Tenaya has granted the underwriters a 30-day option to purchase up to an additional 4,327,500 common shares. Before deducting underwriting rebates and commissions and estimated issuing costs, Tenaya expects total gross proceeds of approximately $75 million, subject to the non-exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about November 21, 2022, subject to satisfaction of customary closing conditions.

Morgan Stanley and Piper Sandler are acting as joint book-running managers for the offering. HC Wainwright & Co. and Chardan are acting as co-lead managers for the offering.

Tenaya has filed a registration statement on Form S-3, which has been declared effective by the SEC, and has filed a preliminary prospectus supplement and an accompanying prospectus relating to the offering. A final prospectus supplement and an accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed free of charge through the SEC’s website at www.sec.gov.

If available, copies of the final prospectus supplement and the accompanying prospectus relating to this…